Dr. Vincent Davisson's lab at Purdue University is focused on developing new treatments to counteract toxic cyanide exposure. The research aims to improve existing countermeasures and explore combinations of agents that can efficiently help individuals affected by chemical threats. By using various animal models, the lab works to ensure that these interventions are both safe and effective in emergency situations, ultimately aiming to protect human health from chemical hazards.

Dr. Danzhou Yang's lab at Purdue University focuses on developing innovative therapies for cancer and inflammatory diseases. The lab investigates the regulation of gene expression, specifically targeting a unique structure in DNA known as a G-quadruplex to suppress the overexpression of a protein called PDGFR-beta, which is implicated in various diseases. By designing and synthesizing small molecular compounds that interact with this structure, the lab aims to create more effective treatments for conditions where PDGFR-beta is a key player.

Dr. Jianing Li's lab at Purdue University focuses on developing innovative peptide-based therapies for Alzheimer's Disease (AD) and related dementias (ADRD). By using advanced generative artificial intelligence (AI), the lab aims to design more effective and safer peptide drugs that can better target the causes of these diseases. The research not only seeks to improve drug development processes but also strives to make peptide therapeutics more accessible to researchers and healthcare providers.

Robert Stahelin's lab at Purdue University focuses on studying deadly viruses like Ebola, Marburg, and SARS-CoV-2. They investigate how these viruses assemble and spread within human cells, aiming to discover new drug targets for treatment. The lab combines computational methods with experimental techniques to understand the viral proteins and their interactions, which is crucial for combating these significant public health threats.

Dr. Yoon Yeo's lab focuses on developing innovative drug delivery systems to treat eye diseases that cause blindness. They are particularly interested in repurposing the old antifungal drug griseofulvin to create long-acting formulations that can be injected into the eye for treating conditions like age-related macular degeneration. By using new polymer-based delivery methods, the lab aims to improve patient outcomes and convenience while reducing the cost of treatment.

Dr. Qi Zhou's lab focuses on improving treatments for serious lung infections caused by multidrug-resistant bacteria, known as 'superbugs.' They are developing more effective ways to deliver antibiotics directly to the lungs using innovative aerosol systems, while minimizing side effects and preventing bacteria from becoming resistant. Their work combines advanced technologies like imaging and machine learning with pharmacological research to enhance patient outcomes in pulmonary medicine.